Evaluation of pathophysiological relationships between renin-angiotensin and ACE-ACE2 systems in cardiovascular disorders: from theory to routine clinical practice in patients with heart failure

References

• Braunwald E. The war against heart failure: the Lancet lecture. Lancet. 2015;385(9970):812–824.
   PubMed Web of Science ®Google Scholar
• Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13(6):368–378.
   PubMed Web of Science ®Google Scholar
• Jones NR, Roalfe AK, Adoki I, et al. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail. 2019;21(11):1306–1325.
   PubMed Web of Science ®Google Scholar
• Murphy SP, Ibrahim NE, Januzzi JL. Heart failure with reduced ejection fraction: a review. JAMA. 2020;324(5):488–504.
   PubMed Web of Science ®Google Scholar
• Basu R, Poglitsch M, Yogasundaram H, et al. Roles of angiotensin peptides and recombinant human ACE2 in heart failure. J Am Coll Cardiol. 2017;69(7):805–819. 2021
   PubMed Web of Science ®Google Scholar
• Braunwald E. Another step toward personalized care of patients with heart failure. Eur J Heart Fail. 2015;17(10):988–990.
   PubMed Web of Science ®Google Scholar
• Vittorini S, Clerico A. Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice. Clin Chem Lab Med. 2008;46:748–763.
   PubMed Web of Science ®Google Scholar
• Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119(17):2408–2416.
   PubMedGoogle Scholar
• Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation. 2011;123(5):551–565.
   PubMed Web of Science ®Google Scholar
• Farmakis D, Mueller C, Apple FS. High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population. Eur Heart J. 2020;41(41):4050–4056.
   PubMed Web of Science ®Google Scholar
• Clerico A, Zaninotto M, Passino C, et al. Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers. Clin Chem Lab Med. 2020;59(1):79–90.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70:735–803.
   Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200.
   PubMed Web of Science ®Google Scholar
• Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315.
   PubMed Web of Science ®Google Scholar
• Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367.
   PubMed Web of Science ®Google Scholar
• Roig E, Perez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 2000;21(1):53–57.
   PubMed Web of Science ®Google Scholar
• Hubers SA, Brown NJ. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation. 2016;133(11):1115–1124.
   PubMed Web of Science ®Google Scholar
• Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417(6891):822–828.
   PubMed Web of Science ®Google Scholar
• Mori J, Patel VB, Abo Alrob O, et al. Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/db mice by reducing lipotoxicity and inflammation. Circ Heart Fail. 2014;7(2):327–339.
   PubMed Web of Science ®Google Scholar
• Patel VB, Zhong JC, Grant MB, et al. Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res. 2016;118(8):1313–1326.
   PubMed Web of Science ®Google Scholar
• Zhong J, Basu R, Guo D, et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation. 2010;122(7):717–728.
   PubMed Web of Science ®Google Scholar
• Mercure C, Yogi A, Callera GE, et al. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res. 2008;103(11):1319–1326.
   PubMed Web of Science ®Google Scholar
• Cabandugama PK, Gardner MJ, Sowers JR. The renin angiotensin aldosterone system in obesity and hypertension: roles in the cardiorenal metabolic syndrome. Med Clin North Am. 2017;101(1):129–137.
   PubMed Web of Science ®Google Scholar
• Rossi F, Mascolo A, Mollace V. The pathophysiological role of natriuretic peptide-RAAS cross talk in heart failure. Int J Cardiol. 2017;226:121–125.
   PubMed Web of Science ®Google Scholar
• Arendse LB, Danser AHJ, Poglitsch M, et al. Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure. Pharmacol Rev. 2019;71(4):539–570.
   PubMed Web of Science ®Google Scholar
• Epelman S, Tang WH, Chen SY, et al. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol. 2008;52(9):750–754.
   PubMed Web of Science ®Google Scholar
• Haschke M, Schuster M, Poglitsch M, et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet. 2013;52(9):783–792.
   PubMed Web of Science ®Google Scholar
• Brojakowska A, Narula J, Shimoni R, et al. Clinical implications of SARS-CoV-2 interaction with renin angiotensin system. JACC review topic of the week. J Am Coll Cardiol. 2020;75:3083–3095.
   Web of Science ®Google Scholar
• Campbell RA, Boilard E, Rondina MT. Is there a role for the ACE2 receptor in SARS-CoV-2 interactions with platelets? J Thromb Haemost. 2021;19(1):46–50.
   PubMed Web of Science ®Google Scholar
• Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ Res. 2020;126(10):1456–1464.
   PubMed Web of Science ®Google Scholar
• Saponaro F, Rutigliano G, Sestito S, et al. ACE2 in the era of SARS-CoV-2: controversies and novel perspectives. Front Mol Biosci. 2020;7:588618.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Vardeny O, Michel T, et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653–1659.
   PubMed Web of Science ®Google Scholar
• Zheng YY, Ma YT, Zhang JY, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259–260.
   PubMed Web of Science ®Google Scholar
• Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87(5):E1–E9.
   PubMed Web of Science ®Google Scholar
• Rice GI, Thomas DA, Grant PJ, et al. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004;383(Pt 1):45–51.
   PubMed Web of Science ®Google Scholar
• Kuba K, Imai Y, Penninger JM. Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases. Circ J. 2013;77(2):301–308.
   PubMed Web of Science ®Google Scholar
• Rice GI, Jones AL, Grant PJ, et al. Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension. 2006;48(5):914–920.
   PubMed Web of Science ®Google Scholar
• Hattori MA, Del Ben GL, Carmona AK, et al. Angiotensin I-converting enzyme isoforms (high and low molecular weight) in urine of premature and full-term infants. Hypertension. 2000;35(6):1284–1290.
   PubMed Web of Science ®Google Scholar
• Wysocki J, Schulze A, Batlle D. Novel variants of Angiotensin Converting Enzyme-2 of shorter molecular size to target the kidney renin angiotensin system. Biomolecules. 2019;9(12):886.
   Web of Science ®Google Scholar
• Guy JL, Lambert DW, Warner FJ, et al. Membrane-associated zinc peptidase families: comparing ACE and ACE2. Biochim Biophys Acta. 2005;1751(1):2–8.
   PubMed Web of Science ®Google Scholar
• Iwai M, Horiuchi M. Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens Res. 2009;32(7):533–536.
   PubMed Web of Science ®Google Scholar
• Bourgonje AR, Abdulle AE, Timens W, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020;251(3):228–248.
   PubMed Web of Science ®Google Scholar
• Yugandhar VG, Clark MA. Angiotensin III: a physiological relevant peptide of the renin angiotensin system. Peptides. 2013;46:26–32.
   PubMed Web of Science ®Google Scholar
• Mustafa T, Lee JH, Chai SY, et al. Bioactive angiotensin peptides: focus on angiotensin IV. J Renin Angiotensin Aldosterone Syst. 2001;2(4):205–210.
   PubMed Web of Science ®Google Scholar
• Stragier B, De Bundel D, Sarre S, et al. Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review. Heart Fail Rev. 2008;13(3):321–337.
   PubMed Web of Science ®Google Scholar
• Cao G, Della Penna S, Kouyoumdzian NM, et al. Immunohistochemical expression of intrarenal renin angiotensin system components in response to tempol in rats fed a high salt diet. World J Nephrol. 2017;6(1):29–40.
   PubMedGoogle Scholar
• He FJ, MacGregor GA. Salt, blood pressure and the renin-angiotensin system. J Renin Angiotensin Aldosterone Syst. 2003;4(1):11–16.
   PubMed Web of Science ®Google Scholar
• Hall JE, Guyton AC, Mizelle HL. Role of the renin-angiotensin system in control of sodium excretion and arterial pressure. Acta Physiol Scand Suppl. 1990;591:48–62.
   PubMedGoogle Scholar
• Ando K, Fujita T. Pathophysiology of salt sensitivity hypertension. Ann Med. 2012;44(sup1):S119–S126.
   PubMed Web of Science ®Google Scholar
• Coelho MS, Lopes KL, de Aquino Freitas K, et al. High sucrose intake in rats is associated with increased ACE2 and angiotensin-(1-7) levels in the adipose tissue. Regul Pept. 2010;162(1–3):61–67.
   PubMedGoogle Scholar
• Mellor KM, Ritchie RH, Davidoff AJ, et al. Elevated dietary sugar and the heart: experimental models and myocardial remodeling. Can J Physiol Pharmacol. 2010;88(5):525–540.
   PubMed Web of Science ®Google Scholar
• Wu L, Shi A, Zhu D, et al. High sucrose intake during gestation increases angiotensin II type 1 receptor-mediated vascular contractility associated with epigenetic alterations in aged offspring rats. Peptides. 2016;86:133–144.
   PubMed Web of Science ®Google Scholar
• Favre GA, Esnault VLM, Van Obberghen E. Modulation of glucose metabolism by the renin-angiotensin-aldosterone system. Am J Physiol Endocrinol Metab. 2015;308(6):E435–E449.
   PubMed Web of Science ®Google Scholar
• Xu CM, Yang TX. New advances in renal mechanisms of high fructose-induced salt-sensitive hypertension. Sheng Li Xue Bao. 2018;70:581–590.
   PubMedGoogle Scholar
• Hernández-Díazcouder A, Romero-Nava R, Carbó R, et al. High fructose intake and adipogenesis. IJMS. 2019;20(11):2787.
   Google Scholar
• Than A, Leow MKS, Chen P. Control of adipogenesis by the autocrine interplays between angiotensin 1-7/Mas receptor and angiotensin II/AT1 receptor signaling pathways. J Biol Chem. 2013;288(22):15520–15531.
   PubMed Web of Science ®Google Scholar
• Bernstein KE, Ong FS, Blackwell WL, et al. A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev. 2013;65(1):1–46.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang Y, Wu L, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cel. 2020;181(4):894–904.e9.
   PubMed Web of Science ®Google Scholar
• Lei C, Qian K, Li T, et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat Commun. 2020;11(1):2070.
   PubMed Web of Science ®Google Scholar
• Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444–1448.
   PubMed Web of Science ®Google Scholar
• Rawat K, Kumari P, Saha L. COVID-19 vaccine: a recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol. 2021;892:173571.
   Web of Science ®Google Scholar
• Rahman N, Basharat Z, Yousuf M, et al. Virtual screening of natural products against type II transmembrane serine protease (TMPRSS2), the priming agent of Coronavirus 2 (SARS-CoV-2). Molecules. 2020;25(10):2271.
   PubMed Web of Science ®Google Scholar
• Pirola CJ, Sookoian S. Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-inhibitor effect on COVID-19 outcome: a meta-analysis. J Infect. 2020;81(2):276–281.
   PubMed Web of Science ®Google Scholar
• Guo X, Zhu Y, Hong Y. Decreased mortality of COVID-19 with renin-angiotensin-aldosterone system inhibitors therapy in patients with hypertension: a meta-analysis. Hypertension. 2020;76(2):e13–e14.
   PubMed Web of Science ®Google Scholar
• Baral R, White M, Vassiliou VS. Effect of renin-angiotensin-aldosterone system inhibitors in patients with COVID-19: a systematic review and meta-analysis of 28,872 patients. Curr Athroscler Rep. 2020;22(10):61.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen B, Li Y, et al. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: a systematic review and meta-analysis. J Med Virol. 2021;93(3):1370–1377.
   PubMed Web of Science ®Google Scholar
• Hasan SS, Kow CS, Hadi MA, et al. Mortality and disease severity among COVID-19 patients receiving renin-angiotensin system inhibitors: a systematic review and meta-analysis. Am J Cardiovasc Res. 2020;20:571–590.
   PubMed Web of Science ®Google Scholar
• Patoulias D, Katsimardou A, Stavropoulos K, et al. Renin-Angiotensin system inhibitors and COVID-19: a systematic review and meta-analysis. Evidence for significant geographical disparities. Curr Hypert Rep. 2020;22(11):90.
   PubMed Web of Science ®Google Scholar
• Koshy AN, Murphy AC, Farouque O, et al. Renin-Angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis. Intern Med J. 2020;50(12):1468–1474.
   PubMed Web of Science ®Google Scholar
• Pranata R, Permana H, Huang I, et al. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Diabetes Metab Syndr. 2020;14(5):983–990.
   PubMed Web of Science ®Google Scholar
• Ssentongo AE, Ssentongo P, Heilbrunn ES, et al. Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis. Open Heart. 2020;7(2):e001353.
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Aikawa T, Takagi H, et al. Association of renin-angiotensin-aldosterone system inhibitors with mortality and testing positive of COVID-19: meta-analysis. J Med Virol. 2021;93(4):2084–2089.
   PubMed Web of Science ®Google Scholar
• Barochiner J, Martínez R. Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: a systematic review and meta-analysis. J Clin Pharm Ther. 2020;45(6):1244–1252.
   PubMed Web of Science ®Google Scholar
• Usman MS, Siddiqi TJ, Khan MS, et al. A meta-analysis of the relationship between renin-angiotensin-aldosterone system inhibitors and COVID-19. Am J Cardiol. 2020;130:159–161.
   PubMed Web of Science ®Google Scholar
• Zhang G, Wu Y, Xu R, et al. Effects of renin-angiotensin-aldosterone system inhibitors on disease severity and mortality in patients with COVID-19: a meta-analysis. J Med Virol. 2021;93(4):2287–2300.
   PubMed Web of Science ®Google Scholar
• Chan CK, Huang YS, Liao HW, et al. Renin-angiotensin-aldosterone system inhibitors and risks of severe acute respiratory syndrome coronavirus 2 infection: a systematic review and meta-analysis. Hypertension. 2020;76(5):1563–1571.
   PubMed Web of Science ®Google Scholar
• Bavishi C, Whelton PK, Mancia G, et al. Renin-angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies. J Hypertens. 2021;39(4):784–794.
   PubMed Web of Science ®Google Scholar
• Sodhi CP, Wohlford-Lenane C, Yamaguchi Y, et al. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg9 bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Am J Physiol Lung Cell Mol Physiol. 2018;314(1):L17–L31.
   PubMed Web of Science ®Google Scholar
• Hrenak J, Simko F. Renin–angiotensin system: an important player in the pathogenesis of acute respiratory distress syndrome. IJMS. 2020;21(21):8038.
   Google Scholar
• Xu Y, Liu S, Zhang Y, et al. Does hereditary angioedema make COVID-19 worse? World Allergy Organ J. 2020;13(9):100454.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 2012;487(7408):477–481.
   PubMed Web of Science ®Google Scholar
• Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(7):667–678.
   PubMed Web of Science ®Google Scholar
• Sultan S, Altayar O, Siddique SM, et al. AGA Institute rapid review of the gastrointestinal and liver manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19. Gastroenterology. 2020;159(1):320.e27–334.e27.
   Web of Science ®Google Scholar
• Paz Ocaranza M, Riquelme JA, García L, et al. Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat Rev Cardiol. 2020;17(2):116–129.
   PubMedGoogle Scholar
• Juillerat-Jeanneret L. The other angiotensin II receptor: AT2R as a therapeutic target. J Med Chem. 2020;63(5):1978–1995.
   PubMed Web of Science ®Google Scholar
• Patel SN, Fatima N, Ali R, et al. Emerging role of angiotensin AT2 receptor in anti-inflammation: an update. Curr Pharm Des. 2020;26(4):492–500.
   PubMed Web of Science ®Google Scholar
• Clerico A, Giannoni A, Vittorini S, et al. Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol. 2011;301(1):H12–H20.
   PubMed Web of Science ®Google Scholar
• Cuthbert JJ, Pellicori P, Clark AL. Cardiovascular outcomes with Sacubitril-Valsartan in heart failure: emerging clinical data. Ther Clin Risk Manag. 2020;16:715–726.
   PubMed Web of Science ®Google Scholar
• Wang J, Li N, Gao F, et al. Balance between angiotensin converting enzyme and angiotensin converting enzyme 2 in patients with chronic heart failure. J Renin Angiotensin Aldosterone Syst. 2015;16(3):553–558.
   PubMed Web of Science ®Google Scholar
• Wang K, Basu R, Poglitsch M, et al. Elevated Angiotensin 1-7/Angiotensin II ratio predicts favorable outcomes in patients with heart failure. Circ Heart Fail. 2020;13:e006939.
   PubMed Web of Science ®Google Scholar
• Clerico A, Passino C, Franzini M, et al. Cardiac biomarker testing in the clinical laboratory: where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. Clin Chim Acta. 2015;443:17–24.
   PubMed Web of Science ®Google Scholar
• Okolicany J, McEnroe GA, Koh GY, et al. Clearance receptor and neutral endopeptidase-mediated metabolism of atrial natriuretic factor. Am J Physiol. 1992;263(3 Pt 2):F546–F553.
   PubMedGoogle Scholar
• Charles CJ, Espiner EA, Nicholls MG, et al. Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol. 1996;271(2 Pt 2):R373–R380.
   PubMedGoogle Scholar
• Campbell DJ. Long-term neprilysin inhibition - implications for ARNIs. Nat Rev Cardiol. 2017;14(3):171–186.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:387–395.
   Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
   PubMed Web of Science ®Google Scholar
• Bayés-Genis A. Neprilysin in heart failure: from oblivion to center stage. JACC Heart Fail. 2015;3:637–640.
   PubMed Web of Science ®Google Scholar
• Packer M, McMurray JJV, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54–61.
   PubMed Web of Science ®Google Scholar
• McCormack PL. Sacubitril/Valsartan: a review in chronic heart failure with reduced ejection fraction. Drugs. 2016;76(3):387–396.
   PubMed Web of Science ®Google Scholar
• Mogensen UM, Gong J, Jhund PS, et al. Effect of sacubitril/valsartan on recurrent events in the prospective comparison of ARNI with ACEI to determine impact on gobal mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2018;20(4):760–768.
   PubMed Web of Science ®Google Scholar
• Clerico A, Zaninotto M, Passino C, et al. New issues on measurement of B-type natriuretic peptides. Clin Chem Lab Med. 2017;56(1):32–39.
   PubMed Web of Science ®Google Scholar
• Yandrapalli S, Khan MH, Rochlani Y, et al. Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy. Ther Adv Cardiovasc Dis. 2018;12(8):217–231.
   PubMedGoogle Scholar
• Morrow DA, Velazquez EJ, DeVore AD, et al. Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. Eur Heart J. 2019;40(40):3345–3352.
   PubMed Web of Science ®Google Scholar
• Velazquez EJ, Morrow DA, DeVore AD, et al. PIONEER-HF Investigators. Angiotensin–neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539–548.
   PubMed Web of Science ®Google Scholar
• Clerico A, Del Ry S, Giannessi D. Measurement of cardiac natriuretic hormones (Atrial Natriuretic Peptide, Brain Natriuretic Peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin Chem. 2000;46(10):1529–1534.
   PubMed Web of Science ®Google Scholar
• Vasan S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113(19):2335–2362.
   PubMed Web of Science ®Google Scholar
• Richards AM. Future biomarkers in cardiology: my favourites. Eur Heart J Suppl. 2018;20(suppl_G):G37–G44.
   Web of Science ®Google Scholar
• Clerico A, Zaninotto M, Padoan A, et al. Evaluation of analytical performance of immunoassay methods for cardiac troponin I and T: from theory to practice. Adv Clin Chem. 2019;93:239–262.
   PubMed Web of Science ®Google Scholar
• Chappell MC. Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? Am J Physiol Heart Circ Physiol. 2016;310(2):H137–H152.
   PubMed Web of Science ®Google Scholar
• Brosnihan KB, Chappell MC. Measurement of angiotensin peptides: HPLC-RIA. Methods Mol Biol. 2017;1527:81–99.
   PubMedGoogle Scholar
• Chappel MC, Pirro NT, South AM, et al. Concerns on the specificity of commercial ELISAs for the measurement of Angiotensin (1-7) and Angiotensin II in human plasma. Hypertension. 2021;77(3):e29–e31.
   PubMed Web of Science ®Google Scholar
• De Mello WC, Gerena Y. Measurement of cardiac angiotensin II by immunoassays, HPLC-chip/mass spectrometry, and functional assays. Methods Mol Biol. 2017;1527:127–137.
   PubMedGoogle Scholar
• Mason DR, Reid JD, Camenzind AG, et al. Duplexed iMALDI for the detection of angiotensin I and angiotensin II. Methods. 2012;56(2):213–222.
   PubMed Web of Science ®Google Scholar
• Reddy R, Asante I, Liu S, et al. Circulating angiotensin peptides levels in acute respiratory distress syndrome correlate with clinical outcomes: a pilot study. PLoS One. 2019;14(3):e0213096.
   PubMed Web of Science ®Google Scholar
• Bellomo R, Wunderink RG, Szerlip H, et al. Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. Crit Care. 2020;24(1):43.
   PubMed Web of Science ®Google Scholar
• Guo Z, Poglitsch M, McWhinney BC, et al. Measurement of equilibrium Angiotensin II in the diagnosis of primary aldosteronism. Clin Chem. 2020;66(3):483–492.
   PubMed Web of Science ®Google Scholar
• Magness RR, Cox K, Rosenfeld CR, et al. Angiotensin II metabolic clearance rate and pressor responses in nonpregnant and pregnant women. Am J Obstet Gynecol. 1994;171(3):668–679.
   PubMed Web of Science ®Google Scholar
• Dai SH, Li JF, Feng JB, et al. Association of serum levels of AngII, KLK1, and ACE/KLK1 polymorphisms with acute myocardial infarction induced by coronary artery stenosis. J Renin Angiotensin Aldosterone Syst. 2016;17(2):1470320316655037.
   Web of Science ®Google Scholar
• Magalhães DM, Nunes-Silva A, Rocha GC, et al. Two protocols of aerobic exercise modulate the counter-regulatory axis of the renin-angiotensin system. Helyion. 2020;6(1):e03208.
   PubMed Web of Science ®Google Scholar
• Sykes SD, Pringle KG, Zhou A, et al. The balance between human maternal plasma angiotensin II and angiotensin 1-7 levels in early gestation pregnancy is influenced by fetal sex. J Renin Angiotensin Aldosterone Syst. 2014;15(4):523–531.
   PubMed Web of Science ®Google Scholar
• Yang CW, Lu LC, Chang CC, et al. Imbalanced plasma ACE and ACE2 level in the uremic patients with cardiovascular diseases and its change during a single hemodialysis session. Ren Fail. 2017;39(1):719–728.
   PubMed Web of Science ®Google Scholar
• Le Goff C, Farre-Segura J, Stoikovic V, et al. The pathway through LC-MS method development: in-house or ready-to-use kit-based methods? Clin Chem Lab Med. 2020;58(6):1002–1009.
   PubMed Web of Science ®Google Scholar
• Grassi J, Créminon C, Frobert Y, et al. Two different approaches for developing immunometric assays of haptens. Clin Chem. 1996;42(9):1532–1536.
   PubMed Web of Science ®Google Scholar
• Santos RAS, Sampaio WO, Alzamora AC, et al. The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on Angiotensin-(1-7). Physiol Rev. 2018;98(1):505–553.
   PubMed Web of Science ®Google Scholar
• Santos RAS, Oudit GY, Verano-Braga T, et al. The renin-angiotensin system: going beyond the classical paradigms. Am J Physiol Heart Circ Physiol. 2019;316(5):H958–H970.
   PubMed Web of Science ®Google Scholar
• Allen AM, Zhuo J, Mendelsohn AO. Localization and function of angiotensin AT1 receptors. Am J Hypert. 2000;13:31S–38S.
   PubMed Web of Science ®Google Scholar
• Singh KD, Karnik S. Angiotensin receptors: structure, function, signaling and clinical applications. J Cell Signal. 2016;1:111.
   PubMedGoogle Scholar
• Chow BSM, Allen TJ. Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease. Clin Sci. 2016;130(15):1307–1326.
   PubMed Web of Science ®Google Scholar
• Kaschina E, Namsolleck P, Unger T. AT2 receptors in cardiovascular and renal diseases. Pharmacol Res. 2017;125(Pt A):39–47.
   PubMedGoogle Scholar
• Azushima K, Morisawa N, Tamura K, et al. Recent research advances in renin-angiotensin-aldosterone system receptors. Curr Hypert Rep. 2020;22:22.
   PubMed Web of Science ®Google Scholar
• Padia SH, Carey RM. AT2 receptors: beneficial counter-regulatory role in cardiovascular and renal function. Pflugers Arch. 2013;465(1):99–110.
   PubMed Web of Science ®Google Scholar
• Sampaio WO, Souza dos Santos RA, Faria-Silva R, et al. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension. 2007;49(1):185–192.
   PubMed Web of Science ®Google Scholar
• Dias-Peixoto MF, Santos RA, Gomes ER, et al. Molecular mechanisms involved in the angiotensin-(1-7)/Mas signaling pathway in cardiomyocytes. Hypertension. 2008;52(3):542–548.
   PubMed Web of Science ®Google Scholar
• Karnik SS, Singh KD, Tirupula K, et al. Significance of angiotensin 1-7 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22. Br J Pharmacol. 2017;174(9):737–753.
   PubMed Web of Science ®Google Scholar
• Li M, Liu K, Michalicek J, et al. Involvement of chymase-mediated angiotensin II generation in blood pressure regulation. J Clin Invest. 2004;114(1):112–120.
   PubMed Web of Science ®Google Scholar
• Wei CC, Hase N, Inoue Y, et al. Mast cell chymase limits the cardiac efficacy of ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest. 2010;120(4):1229–1239.
   PubMed Web of Science ®Google Scholar
• Reilly CF, Tewksbury DA, Schechter NM, et al. Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. J Biol Chem. 1982;257(15):8619–8622.
   PubMed Web of Science ®Google Scholar
• Jorde UP, Ennezat PV, Lisker J, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ace-mediated formation of angiotensin ii in chronic heart failure. Circulation. 2000;101(8):844–846.
   PubMed Web of Science ®Google Scholar
• Petrie MC, Padmanabhan N, McDonald JE, et al. Angiotensin converting enzyme (ace) and non-ace dependent angiotensin ii generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol. 2001;37(4):1056–1061.
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, Jaffe AS, et al. Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardal Infarction. J Am Coll Cardiol. 2018;72:2231–2264.
   PubMed Web of Science ®Google Scholar
• Aimo A, Januzzi JL, Jr, Vergaro G, et al. High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: a multimarker strategy for risk stratification in chronic heart failure. Int J Cardiol. 2019;277:166–172.
   PubMed Web of Science ®Google Scholar
• Aimo A, Januzzi JL, Jr, Mueller C, et al. Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure. Int J Cardiol. 2019;293:137–142.
   PubMed Web of Science ®Google Scholar
• Rørth R, Jhund PS, Kristensen SL, et al. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. Eur J Heart Fail. 2019;21(1):40–49.
   PubMed Web of Science ®Google Scholar
• Bayés-Genis A. Neprelysin in heart failure. From obvious to center stage. J Am Coll Cardiol Heart Fail. 2015;3:637–640.
   PubMed Web of Science ®Google Scholar
• Vodovar N, Séronde M-F, Laribi S, et al. Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure. J Am Coll Cardiol Heart Fail. 2015;3(8):629–636.
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, Barallat J, Galan A, et al. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 2015;65(7):657–665.
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, Barallat J, Pascual D, et al. Prognostic value and kinetics of soluble neprilysin in acute heart failure: a pilot study. J Am Coll Cardiol HF. 2015;3:641–644.
   Google Scholar